SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, N501Y - B 1.1.7 lineage - UK Alpha Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Sequence  YP_009724390.1
Molecular weight35kDa
BufferPBS, pH7.5
Formliquid
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB,,,
Fragment TypeSpike protein fragment
Aliases /SynonymsRBD of VUI V1 UK variant (VOC-202012/01): N501Y, B.1.1.7 lineage; Variant of Concern 202012/01 (VOC-202012/01); clade 20B/501Y.V1; Variant Under Investigation V1 (VUI V1), UK variant, Alpha variant
ReferencePX-COV-P052
Related ProductsBamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade,Anti-RBD-1 (Etesevimab) antibody,Anti-CoV-RBD (E4) antibody,Anti-2019-nCoV(S1) – 2 (H4) antibody,Anti-RBD-4 antibody (Casirivimab),Anti-RBD-5 antibody (Imdevimab),Anti-2019-nCoV(S1)-3 antibody
PublicationsWinklmeier, S. et al. Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv 2021.05.15.21257210. doi: 10.1101/2021.05.15.21257210
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on RBD of VUI V1 UK variant (VOC-202012/01): N501Y

The N501Y mutation in the receptor-binding domain (RBD) has been detected in an emerging variant of SARS-CoV-2. The variant, known as the B.1.1.7 lineage, Variant of Concern (VOC) 202012/01, or clade 20B/501Y.V1, was first discovered in Kent, United Kingdom (UK), in mid-September 2020 and its frequency and distribution continued to grow since then.
The growing number of infections caused by this variant of the new coronavirus has raised causes for concern. The mutation N501Y is located in one of six key residues within the RBD and it has been linked to an enhanced binding affinity towards human ACE2 (angiotensin-converting enzyme 2). The enhancement can also explain the rapid expansion of its geographic distribution and potentially higher infectivity in comparison to other variants of the COVID-19 virus.
Aside from the N501Y mutation, the B.1.1.7 lineage has accumulated 16 additional non-synonymous mutations and deletions within the spike protein (but outside the 320-541 region). The most concerning ones besides the N501Y include:

  • The 69-70del in the N terminal domain of the spike, which has been previously been linked with an enhanced ability to evade the human immune system
  • The P681H mutation adjacent to the furin cleavage site of the spike, a location with high biological significance due to its role in spike cleavage and membrane fusion process

These cumulative mutations are hypothesized to contribute to the increased infectivity and rapid spread of the B.1.1.7 lineage. However, it is still unclear whether this large number of changes in the spike will impact disease severity or even hinder the efficiency of current COVID-19 vaccines.
The 69-70del has also been a cause of difficulty in effective RT-PCR detection kits that target the spike protein of SARS-CoV-2. This has created the need to develop a new assay that will allow the accurate surveillance of the B.1.1.7 variant. Moreover, further studies are needed to elucidate the impact of this set of mutations in the progression of the COVID-19 disease.

SDS-PAGE for SARS-CoV-2 RBD of Spike protein, N501Y - B 1.1.7 lineage - UK Alpha Variant

SARS-CoV-2 RBD of Spike protein, N501Y - B 1.1.7 lineage - UK Alpha Variant, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Publication

Winklmeier, S. et al. Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv 2021.05.15.21257210. doi: 10.1101/2021.05.15.21257210

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant”

Your email address will not be published. Required fields are marked *

Related products

Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031 400€
Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032 400€
Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033 300€
Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637 400€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 185€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.